Effect of Antisense Oligonucleotides on CD34+ Cells from Chronic Myeloid Leukemia

References

• Fialkow P. J., Jacobson R. J., Papayannopoulou T. Chronic myelocytic leukemia : clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and mono-cyte-macrophage. Am J Med 1977; 63: 125–130
   PubMed Web of Science ®Google Scholar
• Nowell P. C., Hungerford D. A. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497–1499
   Web of Science ®Google Scholar
• Shtivelman E., Lifshitz B., Gale R. P., Cananii E. Fused transcript of abl and bcr genes in chronic myel-ogenous leukemia. Nature 1988; 315: 550–554
   Web of Science ®Google Scholar
• Kurzok R., Gutterman J. U., Talpaz M. The molecular genetics of Philadelphia chromosome-positive leu-kemias. New Engl J Med 1988; 319: 990–998
   PubMed Web of Science ®Google Scholar
• Gishisky M. L., Johnson-White J., Wine O. N. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA 1993; 90: 3755–3759
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Deisseroth A., Kurzrock R. Review: chronic myelogenous leukemia : a concise update. Blood 1993; 82: 691–703
   PubMed Web of Science ®Google Scholar
• Allan N. C., Richards S. M., Shepherd PC.A. UK Medical Research Council randomised, multicenter trial of interferon-an 1 for chronic myeloid leukemia : improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392–1397
   PubMed Web of Science ®Google Scholar
• Montastruc M., Mahon F. X., Faberes C., Marit G., Bil-hou-Nabera C, Cony-Makhoul P., Puntous M., Pigneux A., Boiron J. M., Bernard Ph., Salmi R., Broustet A., Reiffers J. Response to Recombinant Interferon Alpha in patients with chronic myelogenous leukemia in a single center : Results, Analysis of predictive factors. Leukemia 1995; 1997–-2002
   PubMed Web of Science ®Google Scholar
• Butturini A., Keating A., Goldman J. Autotrans-plants in chronic myelogenous leukaemia: strategies and results. Lancet 1990; 335: 1255–1260
   PubMed Web of Science ®Google Scholar
• Reiffers J., Goldman J., Meloni G., Cahn J. Y., Grat-wohl A. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14: 407–410
   PubMed Web of Science ®Google Scholar
• Carella A. M., Podesta M., Frassoni F., Raffo M. R., Polli-cardo N., Pungolino E., Vimercati R., Sessarego M., Par-odi C., Rabitti C. Collection of normal blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993; 12: 267–271
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C, Mangoni L., Almici C. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 1994; 14: 425–432
   PubMed Web of Science ®Google Scholar
• Barnett M., Eaves C, Gordon L., Gascoyne R., Hogge D., Horsman D., Humphries R., Klingemann H., Lansdorp P., Nantel S., Reece D., Shepherd J., Spinelli J., Sutherland H., Eaves A. Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study. Blood 1994; 84: 724–732
   PubMed Web of Science ®Google Scholar
• Skorski T., Nieborowska-Skorska M., Barleta C, Malaguarnera L., Szczylick C, Chen ST., Lange B., Calabretta B. Highly efficient elimination of Philadelphia1 leukemic cells by exposure to bcr/abl antisense oli-godeoxynucleotides combined with mafosfamide. J Clin Invest 1993; 93: 194–202
   Web of Science ®Google Scholar
• Skorski T., Szczylick C, Malaguarnera L., Calabretta B. Gene targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeox-ynucleotides. Folia Histochem Cytobiol 1991; 29: 85–89
   PubMed Web of Science ®Google Scholar
• Mahon EX., Belloc F., Reiffers J. Antisense oli-gomers in chronic myeloid leukemia. Lancet 1993; 341: 566
   PubMed Web of Science ®Google Scholar
• Chasty R., Whetton A., Lucas G. A Comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotide on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations. Leukemia Research 1996; 20: 391–395
   PubMed Web of Science ®Google Scholar
• De Fabritiis P., Amadori S., Calabretta B., Mandelli F. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant 1993; 12: 261–265
   PubMed Web of Science ®Google Scholar
• Kirkland M. A., Brien O., Me Donald C, Davidson R. J., Cross N. C. P., Goldman J. BCR-ABL antisense purging in chronic myeloid leukemia. Lancet 1993; 42: 614
   Web of Science ®Google Scholar
• Verfaillie CM., Miller W. J., Boylan K. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003–1010
   PubMed Web of Science ®Google Scholar
• Law P., Ishizawa L., Van De Ven C., Cairo M., Gee A. Selection of CD34+ cells from large quantities of human bone marrow by immunomagnetic procedures Exp. Hematol 1992; 20: 740–746
   Web of Science ®Google Scholar
• Malinge M. C., Mahon F. X., Daheron L., Kitzis A., Delfau M. H., Guilhot F., Tanzer J, Grandchamp B. Quantitative determination of the hybrid BCR-ABL mRNA in patients with chronic myelogenous leukemia under interferon therapy. Br J Haematol 1992; 82: 701–707
   PubMed Web of Science ®Google Scholar
• Singer J. M., Arlin Z., Najfeld V., Adamson W., Kempin S. J., Clarckson B. D., Fialkow P. J. Restoration of non-clonal hematopoiesis in chronic myelogenous leukemia (CML) following a chemotherapy-induced loss of the Ph1 chromosome. Blood 1980; 56: 356–360
   PubMed Web of Science ®Google Scholar
• Talpaz M., Me Credie K. B., Mavlight G. M., Gutter-man J. U. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983; 62: 689–692
   PubMed Web of Science ®Google Scholar
• Hughes T.P., Brito-Babapulle F., Tollit D. J., Martiat P., Bowcok S., Th'ng K.H., Dowding C., Goldman J. M. (1991) Induction of Philadelphia negative hemopoiesis and prolongation of chronic phase in patients with chronic myeloid leukemia treated with high dose chemotherapy and transfusion of peripheral blood stem cells. In Autologous Bone Marrow Transplantation: Proceedings of the Fifth Internationa) Symposium. 1991, K Dicke, J O Armitage, Dicke-Evinger. University of Nebraska Medical Center, Omaha, NE. 219, (Abstract)
   Google Scholar
• Turhan A. G., Humphries R. K., Eaves C. G., Barnett M. J., Phillips G.L, Kalousek D. K., Klingemann H. G., Lansdorg PL., Reece D. E., Sheperd J. D. Detection of breakpoint cluster region-negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow. Blood 1990; 76: 2404–2410
   PubMed Web of Science ®Google Scholar
• Stein C. A. Does antisense exist?. Nature medicine 1995; 11: 1119–1121
   Web of Science ®Google Scholar
• De Fabritiis P., Skorski T., De Propis M. S., Paggi M. G., Nieborowska-Skorska M., Lisci A., Buffolino S., Campbell K., Geiser T., Calabretta B. Effect of bcr-abl oligonucleotides on the clonogenic growth of chronic myelogenous leukaemia cells. Leukemia 1997; 11: 811–819
   PubMed Web of Science ®Google Scholar
• Letheby B. A., Jackson J. D., Whalen V. L., Bishop M. R., Iversen P. L., Sharp J. G., Kessinger A., Armitage J. O., Warkentin P. L. Ex vivo treatment of normal peropheral blood-derived progenitor cells with antisense bcr-abl oligonucleotides; Exper. Hematol. 1994; 22: 778
   Web of Science ®Google Scholar
• Smetsers T., Van De Locht L., Pennings A., Wessels M. C., De Witte T., Mensik E. Phosphorotiate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular Bcr-Abl protein levels. Leukemia 1995; 9: 118–130
   PubMed Web of Science ®Google Scholar
• O'Brien S. G., Kirkland M. A., Melo J. V., Rao M;H., Davidson R. J., Me Donald C., Goldman J. M. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell line. Leukemia 1994; 8: 2156–2162
   PubMed Web of Science ®Google Scholar
• Mahon E X, Ripoche J., Pigeonnier V., Jazwieck B., Pigneux A., Moreau J. F., Reiffers J. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABI B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp Hematol 1995; 23: 1606–1611
   PubMed Web of Science ®Google Scholar
• Evans C, Owen-Lynch J., Whetton A., Dive C. Activation of Abelson tyrosine kinase activity is associated with suppression of apoptosis in hematopoietic cells. Cancer Res 1993; 53: 1735–1738
   PubMed Web of Science ®Google Scholar
• Vaerman J. L., Lammineur C, Moureau P., Lewalle P., Deldime R, Blumenfeld M., Martiat P. Bcr-Abl antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 1995; 86: 3891–3896
   PubMed Web of Science ®Google Scholar
• Ratajczak M. Z., Hiji N., Catani L. Acute and chronic phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 1992; 79: 1956–1961
   PubMed Web of Science ®Google Scholar
• De Fabritiis P., Amadori S., Petti M. C., Mancini M., Mon-tefusco E., Picardi A., Geiser T., Campbell K., Calabretta B., Mandelli F. In vitro purging with BCR-ABL antisense oligonucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia 1995; 9: 662–667
   PubMed Web of Science ®Google Scholar